IPO
IPO filing, visualized

Aspen Neuroscience, Inc.

ASPE · Nasdaq424B4 · Oct 30, 2026Priced Oct 29, 2026

Priced Oct 29, 2026 · range was $15–$17 · latest SEC filing Nov 9, 2026.

Pinch-zoom for details.

The offering

Final price
$15.00
per share, from the final prospectus
Shares offered
9.38M
sold by the company
Raise at the final price
$141M
9,375,000 × $15, before fees

What the company does

Clinical-stage biotech developing stem-cell therapies made from a patient's own cells (iPSC-derived) for neurodegenerative diseases; its lead candidate is sasineprocel.

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $36.5M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Operating result(53.5M)(59.3M)−10.9%(30.9M)(38.2M)−23.7%
Net result(48.6M)(62.1M)−27.8%(31.8M)(36.5M)−15.1%
$FY2024FY2025YoY
Operating result(53.5M)(59.3M)−10.9%
Net result(48.6M)(62.1M)−27.8%
$H1 2025H1 2026Change
Operating result(30.9M)(38.2M)−23.7%
Net result(31.8M)(36.5M)−15.1%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. We are a clinical-stage regenerative medicine biotechnology company with a limited operating history and no history of commercializing products…
  2. We have incurred substantial operating losses since our inception and expect to incur substantial losses for the foreseeable future
  3. Our financial condition raises substantial doubt as to our ability to continue as a going concern
  4. We currently depend on the success of sasineprocel, which is our lead product candidate
  5. Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes…

The filing's own risk-factor headings, shortened.

Strategy

  1. Advance sasineprocel, our personalized potentially disease-modifying product candidate for PD patients, through Phase 3 trials for sporadic PD
  2. Expand development of sasineprocel into genetic PD and maximize the therapeutic potential of sasineprocel across PD patients
  3. Build scalable, automated autologous cell manufacturing to support potential commercialization in North America (United States…
  4. Maximize the commercial opportunity of sasineprocel and opportunistically engage in strategic collaborations
  5. Expand our pipeline by leveraging our platform to identify and develop additional product candidates in CNS indications where cell replacement…

The filing's own strategy headings, shortened.

Source: Aspen Neuroscience, Inc.'s Form 424B4, filed with the SEC on Oct 30, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.